



COVID-19 Treatment and Vaccine Tracker

This document contains an aggregation of publicly available information from validated sources. It is not an endorsement of one approach or treatment over another but simply a list of all treatments and vaccines currently in development.

TREATMENTS

Number	Type of Product - Treatment	FDA-Approved Indications	Clinical Trials for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
ANTIBODIES										
1	Polyclonal hyperimmune globulin (H-IG), formerly known at TAK-888	N/A		Alliance among Takeda, CSL Behring, Biotest AG, Bio Products Laboratory, LFB, and Octapharma	Pre-clinical			Begin Phase 1 trials in late spring. To patients between December 2020 and December 2021		PhRMA Wall Street Journal Pink Sheet Press release from the alliance
2	Antibodies from mice, REGN3048-3051, against the spike protein	N/A		Regeneron	Pre-clinical	Biomedical Advanced Research and Development Authority (BARDA)		Start Phase 1 June 2020		Stat News MarketWatch Reuters Bloomberg News FierceBiotech FiercePharma
3	Antibodies from recovered COVID-19 patients	N/A		Celltrion	Pre-clinical			Start Phase 1 in July 2020		Korea Herald UPI Celltrion press release
4	Super-antibody or antibody cocktail to target potential mutations of SARS-CoV-2	N/A		Celltrion	Pre-clinical					Celltrion press release
5	Antibodies from recovered COVID-19 patients	N/A		Kamada	Pre-clinical					BioSpace AbbVie
6	Antibodies from recovered COVID-19 patients	N/A		Vir Biotech/WuXi Biologics/Biogen	Pre-clinical			Start Phase 1 ~ July 2020		Stat News Vir Biotech Vir Biotech

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
7	VIR-7831 and VIR-7832, antibodies from recovered COVID-19 patients	N/A		Vir Biotech/GSK/Samsung	Pre-clinical			Start Phase 2 ~ July-September 2020		Vir Biotech Samsung and Vir press release
8	Antibodies from recovered COVID-19 patients	N/A		Eli Lilly/Ab-Cellera (NIH Vaccines Research Center)	Pre-clinical	Defense Advanced Research Projects Agency		Start Phase 1 in late July 2020		Endpoints News AbCellera
9	Avastin (bevacizumab), vascular endothelial growth factor inhibitor	FDA-approved since 2004, approved to treat certain types of cancer		Numerous trials with Chinese research sponsors; Roche	Clinical		NCT04275414 (Qilu Hospital of Shandong University) pilot study NCT04305106 (Qilu Hospital of Shandong University) investigational study			BioCentury
10	PD-1 blocking antibody; Thymosin	Unknown		Numerous trials with Chinese research sponsors	Clinical		NCT04268537 ChiCTR2000030028	Phase 2 primary trial ends April 30, 2020		BioCentury
11	leronlimab (PRO 140), a CCR5 antagonist	N/A	Treatment of HIV/AIDS, Graft versus Host Disease, Non-Alcoholic Steatohepatitis, and numerous cancers	CytoDyn	Clinical/Compassionate Use		NCT04343651 (CytoDyn, Inc.) NCT04347239 (CytoDyn, Inc.)	Phase 2 trial started in April 2020; Phase 2b/3 trial starts April 2020	CytoDyn	Clinical Trials Arena CytoDyn CytoDyn CytoDyn CytoDyn CytoDyn
12	AiRuiKa (camrelizumab), anti-programmed cell death protein (PD-1) antibody	N/A	Treatment of certain cancers	Wuhan Jinyintan Hospital	Clinical		ChiCTR2000029806			Hengrui Medicine

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
13	Kevzara (sarilumab), interleukin-6 receptor antagonist	FDA-approved since 2017, approved to treat rheumatoid arthritis		Sanofi/Regeneron; Feinstein Institutes; REMAP-CAP global trial	Clinical	Biomedical Advanced Research and Development Authority (BARDA)	NCT04315298 NCT04321993 (Lisa Barrett, Nova Scotia Health Authority) (lopinavir/ritonavir; hydroxychloroquine; baricitinib; sarilumab) NCT04341870 (Assistance Publique - Hôpitaux de Paris) (sarilumab, azithromycin, hydroxychloroquine; CORIMUNO-VIRO trial) NCT04324073 (Assistance Publique - Hôpitaux de Paris) (CORIMUNO-SARI trail) NCT04327388 (Sanofi/Regeneron) NCT04322773 (Marius Henriksen, Frederiksberg University Hospital) (Kevzara, Actemra) NCT04345289 (Thomas Benfield, Hvidovre University Hospital) (convalescent anti-SARS-CoV-2 plasma; sarilumab; baricitinib; hydroxychloroquine) NCT02735707 (MJM Bonten, UMC Utrecht) (REMAP-CAP trial)	Started Phase 2/3 in March 2020; initial data expected April 2020		FiercePharma Wall Street Journal Seeking Alpha Regeneron Reuters MedicalCountermeasures.gov Feinstein Institutes press release

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
14	Actemra (tocilizumab), interleukin-6 receptor antagonist	FDA-approved since 2010, approved to treat various type of arthritis, including rheumatoid arthritis, and cytokine release syndrome		Numerous trials with global research sponsors; Roche	Clinical	Biomedical Advanced Research and Development Authority (BARDA)	NCT04317092 (National Cancer Institute, Naples) NCT04320615 (Roche) NCT04310228 (Peking University First Hospital) (also tocilizumab + favipiravir); ChiCTR2000030894 NCT04306705 (Tongji Hospital) (Cytokine Release Syndrome) ChiCTR2000030442 (The Second Affiliated Hospital of Xi'an Jiaotong University) (combination of Tocilizumab, IVIG and CRRT) ChiCTR2000029765 (The First Affiliated Hospital of University of Science and Technology of China [Anhui Provincial Hospital]) NCT04322773 (Marius Henriksen, Frederiksberg University Hospital) (Kevzara, Actemra)	Roche studies begin April 2020	ChinaXiv	Wall Street Journal FiercePharma Genentech FiercePharma
15	Gimsilumab, anti-granulocyte-macrophage colony stimulating factor monoclonal	N/A		Roivant Sciences	Clinical			Phase 2 study started in April 2020		Roivant Roivant
16	TJM2 (TJ003234), anti-granulocyte-macrophage colony stimulating factor antibody	N/A		I-Mab Biopharma	Clinical					i-Mab Biopharma

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
17	lenzilumab, anti-granulocyte-macrophage colony stimulating factor antibody	N/A	Prevent cytokine storm with CAR-T cancer therapy; prevention/treatment of acute graft versus host disease; chronic myelomonocytic leukemia; eosinophilic asthma	Humanigen Inc.	Clinical / Compassionate Use					BioWorld Humanigen Humanigen Humanigen
18	Sylvant (siltuximab), interleukin-6 targeted monoclonal	FDA-approved since 2014, approved to treat multicentric Castleman disease		EUSA Pharma/The Papa Giovanni XXII Hospital	Clinical		NCT04322188 (A.O. Ospedale Papa Giovanni XXIII)	Interim data shared April 2020	EUSA Pharma medRxiv	EUSA Pharma
19	Soliris (eculizumab), complement inhibitor	FDA-approved since 2007, approved to treat Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis, and Neuromyelitis Optica Spectrum Disorder		Alexion	Clinical/Expanded access		NCT04288713 (Hudson Medical) (expanded access trial)	Phase 2 to start in April 2020		Alexion GlobalData
20	Ilaris (canakinumab), interleukin-1beta blocker	FDA approved since 2009, approved to treat periodic fever syndromes and systemic juvenile idiopathic arthritis		Novartis	Clinical					Reuters
21	Gamifant (emapalumab), anti-interferon gamma antibody	FDA-approved since 2018, approved to treat primary hemophagocytic lymphohistiocytosis		Swedish Orphan Biovitrum	Clinical		NCT04324021 (Swedish Orphan Biovitrum), (Emapalumab; Anakinra)			
22	meplazumab, anti-CD147 antibody	N/A		Tang-Du Hospital	Clinical		NCT04275245 (Tang-Du Hospital)		medRxiv	

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
23	LY3127804, anti-Angiopoietin 2 (Ang2) antibody	N/A		Eli Lilly	Clinical			Phase 2 to start in April 2020		Eli Lilly
24	Antibody	N/A		Erasmus MC/Utrecht University	Pre-clinical					Erasmus Magazine bioRxiv
25	Antibodies	Unknown		ImmunoPrecise Antibodies	Pre-clinical					Clinical Trials Arena
26	Antibody	N/A		Harbour BioMed/Mount Sinai Health System	Pre-clinical					Mount Sinai and Harbour BioMed press release
27	Antibodies targeting the S protein from convalescent serum, humanized mice, and phage display	N/A		AstraZeneca/US Army Medical Research Institute of Infectious Diseases (USAMRIID)/University of Maryland School of Medicine	Pre-clinical			Phase 1 trials begin in summer 2020		PhRMA AstraZeneca
28	Antibody	Unknown		Distributed Bio	Pre-clinical					Distributed Bio
29	Antibodies	Unknown		Chelsea and Westminster Hospital, Imperial College London	Pre-clinical	UK Government				UK Government
30	Antibody	N/A		Vanderbilt Vaccine Center	Pre-clinical	Defense Advanced Research Projects Agency		Phase 1 trial begins in summer 2020		Nashville Post
31	Antibodies	N/A		Medicago/ Laval University's Infectious Disease Research Centre	Pre-clinical	Canadian Institutes for Health Research (CIHR)				Medicago press release
32	Polyclonal hyperimmune globulin (H-IG)	N/A	Same human hyperimmune platform as FDA-approved anthrax treatment (Anthraxil) and smallpox vaccine complications (VIGIV) were developed	Emergent BioSolutions/ National Institute of Allergy and Infectious Diseases (NIAID)	Pre-clinical	Biomedical Advanced Research and Development Authority (BARDA)		Phase 2 trials begin ~ August 2020		TechCrunch Emergent Biosolutions Pink Sheet Emergent BioSolutions
33	Horse plasma product (COVID-EIG)	N/A	Same equine hyperimmune platform as FDA-approved botulism anti-toxin (BAT) is produced	Emergent BioSolutions	Pre-clinical			Phase 2 trials begin ~ August 2020		TechCrunch Emergent Biosolutions Pink Sheet Emergent BioSolutions

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
34	Convalescent plasma (blood plasma from recovered patients)	N/A		Multiple global research sponsors, including New York State Department of Health, Johns Hopkins University, the Feinstein Institutes	Clinical/Expanded Access	Bloomberg Philanthropies and the State of Maryland (to Johns Hopkins University)	NCT04321421 (Foundation IRCCS San Matteo Hospital) NCT04292340 (Shanghai Public Health Clinical Center) NCT04316728 (Centro Studi Internazionali, Italy) NCT04338360 (Mayo Clinic) (Expanded Access) NCT04345289 (Thomas Benfield, Hvidovre University Hospital) (convalescent anti-SARS-CoV-2 plasma; sarilumab; baricitinib; hydroxychloroquine)	New York State Department of Health trial begins March 2020	medRxiv JAMA Network medRxiv JAMA Network	Politico Johns Hopkins University Feinstein Institutes press release
35	Antibodies from recovered COVID-19 patients	N/A		Tsinghua University/Third People's Hospital of Shenzhen/Brii Biosciences	Pre-clinical			Phase 1 trial begins Q3 2020		Tsinghua University press release End Points News
36	Polyclonal hyperimmune globulin (H-IG)	N/A		Grifols	Pre-clinical	Biomedical Advanced Research and Development Authority (BARDA)				MedicalCountermeasures.gov
37	Antibodies from recovered COVID-19 patients	N/A		Grifols	Pre-clinical	Biomedical Advanced Research and Development Authority (BARDA)				Grifols MedicalCountermeasures.gov

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
38	Antibodies from recovered COVID-19 patients	N/A		Amgen/Adaptive Biotechnologies	Pre-clinical					Amgen
39	Antibodies from recovered COVID-19 patients	N/A		Innovent Biologics	Pre-clinical					Endpoints News
40	Antibodies from recovered COVID-19 patients	N/A		Xbiotech/BioBridge Global	Pre-clinical					Xbiotech and BioBridge press release
41	Antibodies from recovered COVID-19 patients	N/A		Costa Rican Social Security Fund (CCSS)/The University of Costa Rica (UCR)/Clodomiro Picado Institute	Pre-clinical					MENAFN
42	SAB-185, Polyclonal hyperimmune globulin (H-IG)	N/A		CSL Behring/SAb Biotherapeutics	Pre-clinical	Biomedical Advanced Research and Development Authority (BARDA)		Phase 1 starts early summer 2020		CSL Behring SAB Biotherapeutics
43	Non-viral gene therapy to produce monoclonal antibodies	N/A		Generation Bio/Vir Biotechnology	Pre-clinical					Generation Bio
44	rCIG (recombinant anti-coronavirus 19 hyperimmune gammaglobulin), polyclonal antibodies	N/A		GigaGen	Pre-clinical					FierceBiotech
45	IC14, recombinant chimeric anti-CD14 monoclonal antibody	N/A	Acute Respiratory Distress Syndrome	Implicit Bioscience	Expanded access		NCT04346277 (Implicit Bioscience) (Expanded Access)			

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
ANTIVIRALS										
46	Favilavir/Favipiravir/T-705/ Avigan, licensed in Japan to treat influenza	N/A		Fujifilm Toyama Chemical/Zhejiang Hisun Pharmaceuticals/numerous trials with global research sponsors/ Brigham and Women's Hospital, Massachusetts General Hospital, and the University of Massachusetts Medical School	Clinical		NCT04303299 (Rajavithi Hospital) (Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine) NCT04310228 (Peking University First Hospital) (also tocilizumab + favipiravir) ChiCTR2000029548 (The First Affiliated Hospital, Zhejiang University School of Medicine) (Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir) ChiCTR2000029496 (Hu'nan Haiyao hongxingtang Pharmaceutical Co., Ltd) (Novaferon, Kaletra, Novaferon+Kaletra) ChiCTR2000029544 (The First Hospital Affiliated to Zhejiang University's Medical School) (Baloxavir Marboxil, Favipiravir) ChiCTR2000030254 (Zhongnan Hospital of Wuhan University)	Phase 3 trial in Japan started in March 2020; Phase 2 trial in US started April 2020	medRxiv	World Health Organization Clinical Trials Arena Pharmaceutical Technology BioCentury Guardian Fujifilm

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
46 (cont.)	Favilavir/Favipiravir/T-705/ Avigan, licensed in Japan to treat influenza						NCT04336904 (Giuliano Rizzardini, ASST Fatebenefratelli Sacco) NCT04333589 (Peking University First Hospital) NCT04345419 (Tanta University) (chloroquine; favipiravir; nitazoxanide; ivermectin; niclosamide)			

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
47	Kaletra/Aluvia (lopinavir/ritonavir), HIV-1 protease inhibitor	FDA-approved since 2000, approved to treat HIV-1 infection		Global hospital testing (AbbVie); World Health Organization SOLIDARITY trial (studying lopinavir/ritonavir with and without interferon beta); University of Oxford RECOVERY trial; REMAP-CAP global trial	Clinical	UK Government (University of Oxford RECOVERY trial)	NCT04303299 (Rajavithi Hospital) (Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine) NCT04255017 (Tongji Hospital) (Abidol Hydrochloride, Oseltamivir and Lopinavir/Ritonavir) ChiCTR2000029548 (The First Affiliated Hospital, Zhejiang University School of Medicine) (Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir) ChiCTR2000029539 (Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology) EudraCT 2020-000936-23, INSERM study (lopinavir/ritonavir; Rebif; remdesivir) NCT04307693 (Asan Medical Center) (Lopinavir/Ritonavir or Hydroxychloroquine) NCT04315948 (Institut National de la Santé Et de la Recherche Médicale, France) (remdesivir, lopinavir/ritonavir, interferon beta-1a, hydroxychloroquine)	RECOVERY trial results expected by June 2020*	New England Journal of Medicine medRxiv Chinese Journal of Infectious Diseases medRxiv	PhRMA Wall Street Journal Wall Street Journal Wall Street Journal Stat News UK Government REMAP-CAP RECOVERY Trial Endpoints News*

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
47 (cont.)	Kaletra/Aluvia (lopinavir/ritonavir), HIV-1 protease inhibitor						NCT04252885 (Guangzhou Eighth People's Hospital) (Lopinavir Plus Ritonavir; Arbidol) NCT04276688 (The University of Hong Kong) (Lopinavir/ritonavir; ribavirin; interferon beta-1B) NCT02735707 (MJM Bonten) (REMAP-CAP global trial) NCT04321993 (Lisa Barrett, Nova Scotia Health Authority) (lopinavir/ritonavir; hydroxychloroquine; baricitinib; sarilumab) 2020-001113-21 (RECOVERY Trial) (lopinavir-ritonavir; low-dose dexamethasone, hydroxychloroquine, azithromycin)			

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
48	remdesivir, nucleotide analog	N/A	Treatment of Ebola	Gilead; World Health Organization SOLIDARITY trial; National Institute of Allergy and Infectious Disease (NIAID)'s Adaptive COVID-19 Treatment Trial; Feinstein Institutes	Clinical/Expanded Access		NCT04257656 (Capital Medical University), China study in patients with severe disease NCT04252664 (Capital Medical University), China study in patient with mild/moderate disease NCT04292730, Gilead study in patients with moderate disease NCT04292899, Gilead study in patients with severe disease NCT04280705, NIAID study EudraCT 2020-000936-23, INSERM study NCT04315948 (Institut National de la Santé Et de la Recherche Médicale, France) (remdesivir, lopinavir/ritonavir, interferon beta-1a, hydroxychloroquine) NCT04302766 (Intermediate-size population Expanded Access) NCT04323761 (Gilead Sciences) (Expanded Access)	Gilead Phase 3 trial results expected April 2020 (severe disease) and May 2020 (moderate disease); NIAID trial results expected in May 2020	New England Journal of Medicine New England Journal of Medicine Stat News*	PhRMA Wall Street Journal PhRMA post on LinkedIn Stat News Seeking Alpha Gilead Endpoints News FierceBiotech Gilead press release Feinstein Institutes press release

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
49	Prezcobix (darunavir, HIV-1 protease inhibitor/cobicistat, CYP3A inhibitor)	FDA-approved since 2015, approved to treat HIV-1 infection		Chinese hospital testing (Janssen)	Clinical		ChiCTR2000029541 (Zhongnan Hospital of Wuhan University) (darunavir/cobicistat; lopinavir/ritonavir + thymosin a1) NCT04252274 (Shanghai Public Health Clinical Center) NCT04303299 (Rajavithi Hospital) (Various combination of protease inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine) NCT04304053 (Fundacio Lluita Contra la SIDA) (prevention, darunavir/cobicistat or hydroxychloroquine)	Primary study ends August 2020		World Health Organization Wall Street Journal
50	galidesivir	N/A	Treatment of yellow fever	BioCryst Pharmaceuticals	Clinical	National Institute of Allergy and Infectious Diseases (NIAID)	NCT03891420 (BioCryst Pharmaceuticals)	Phase 1b to start April 2020		Reuters BioCryst BioCryst
51	Combination of ebastine, lopinavir, and interferon alpha	N/A		Mianyang Central Hospital	Clinical		ChiCTR2000030535 (Mianyang Central Hospital)	Primary trial ends March 31, 2020		BioCentury
52	Ganovo (danoprevir), hepatitis C virus NS3 protease inhibitor; ritonavir; interferon, approved in China to treat Hepatitis C	N/A		Ascletris/Numerous trials with Chinese research sponsors	Clinical		NCT04291729 (The Ninth Hospital of Nanchang)		medRxiv	BioCentury ClinicalTrials.gov

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
53	ASC09, HIV protease inhibitor	N/A	Treatment of HIV/AIDS	Asclepis Pharma	Clinical		NCT04261907 (The First Affiliated Hospital of Zhejiang University) (ASC09/Ritonavir and Lopinavir/Ritonavir) NCT04261270 (Tongji Hospital) (ASC09F+Oseltamivir; Ritonavir+Oseltamivir; Oseltamivir)	Primary trial ends May 2020		Nature Biotechnology Asclepis Pharma
54	Truvada (emtricitabine and tenofovir, both HIV-1 nucleoside analog reverse transcriptase inhibitors)	FDA-approved since 2004, approved to treat and prevent HIV-1 infection		Gilead/Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital	Clinical		ChiCTR2000029468 (Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital)			World Health Organization
55	Arbidol (umifenovir), licensed in Russia and China for treatment of respiratory viral infections	N/A		Pharmstandard/numerous trials with Chinese research sponsors	Clinical		NCT04252885 (Guangzhou Eighth People's Hospital) (Lopinavir Plus Ritonavir; Arbidol)		medRxiv Chinese Journal of Infectious Diseases medRxiv medRxiv medRxiv	World Health Organization BioCentury
56	Xofluza (baloxavir marboxil), polymerase acidic endonuclease inhibitor	FDA-approved since 2018, approved to treat influenza		Roche/The First Affiliated Hospital of Zhejiang University Medical School	Clinical		ChiCTR2000029544 (The First Hospital Affiliated to Zhejiang University's Medical School) (Baloxavir Marboxil, Favipiravir) ChiCTR2000029548 (The First Affiliated Hospital, Zhejiang University School of Medicine) (Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir)			World Health Organization

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
57	azvudine, reverse transcriptase inhibitor	N/A		Numerous trials with Chinese research sponsors	Clinical		ChiCTR2000030487 (He'nan Sincere Biotechnology Co., Ltd) ChiCTR2000030424 (He'nan Sincere Biotechnology Co., Ltd) ChiCTR2000029853 (People's Hospital of Guangshan County)			World Health Organization
58	Vicromax, broad spectrum antiviral			ViralClear Pharmaceuticals	Pre-clinical					AP
59	ISR-50	N/A		ISR Immune System Regulation	Pre-clinical					ISR Immune System Regulation
60	Tamiflu (oseltamivir), neuraminidase inhibitor	FDA-approved since 1999, approved to treat and prevent influenza		Roche; REMAP-CAP global trial	Clinical		NCT04303299 (Rajavithi Hospital) (Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine) NCT04255017 (Tongji Hospital) (Abidol Hydrochloride, Oseltamivir and Lopinavir/ Ritonavir) NCT04261270 (Tongji Hospital) (ASC09F+Oseltamivir; Ritonavir+Oseltamivir; Oseltamivir) NCT02735707 (MJM Bonten, UMC Utrecht) (REMAP-CAP trial)			
61	antiviral Fc conjugates	N/A		Cidara Therapeutics	Pre-clinical					Cidara Therapeutics
62	Antiviral compounds	N/A		Cocrystal Pharma	Pre-clinical					Cocrystal Pharma

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
63	EIDD-2801, oral ribonucleoside analog	N/A		Ridgeback Biotherapeutics/Drug Innovation Ventures at Emory (DRIVE)	Clinical			Phase 1 started April 2020		Ridgeback Biotherapeutics press release Ridgeback Biotherapeutics press release Ridgeback Biotherapeutics press release
64	Virazole (ribavirin for inhalation solution)	FDA-approved since 1985, approved to treat lower respiratory tract infections due to RSV		Bausch Health	Clinical/ Compassionate Use					Bausch Health
65	Antiviral drug combinations	Unknown		SCORE consortium (universities of Aix-Marseille, Leuven, Utrecht, Bern, and Lubeck), the Helmholtz Centre for Infection Research, and Janssen Pharmaceutica NV	Pre-clinical	EU Commission (Horizon 2020 Program)				Leiden University Medical Center
CELL-BASED THERAPIES										
66	PLX cell product, placenta-based cell therapy	Unknown		Pluristem Therapeutics/BIH Center for Regenerative Therapy/Berlin Center for Advanced Therapies	Pre-clinical					Pharmaceutical Technology Pluristem Therapeutics

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
67	Mesenchymal stem cells	Unknown		Numerous trials with global research sponsors	Clinical		ChiCTR2000029990 (Institute of Basic Medicine, Chinese Academy of Medical Sciences) NCT04315987 (Azidus Brasil) (NestCell®) NCT04302519 (CAR-T [Shanghai] Biotechnology Co., Ltd.) (Dental Pulp Mesenchymal Stem Cells) NCT04288102 (Beijing 302 Hospital/VCANBIO CELL & GENE ENGINEERING CORP.,LTD, China) NCT04313322 (Stem Cells Arabia) (Wharton's Jelly-Mesenchymal Stem Cells) NCT04273646 (Wuhan Union Hospital, China/Wuhan Hamilton Bio-technology Co., Ltd, China) (Human Umbilical Cord Mesenchymal Stem Cells)		Aging and Disease ChinaXiv	BioCentury
68	Autologous Adipose-Tissue Derived Mesenchymal Stem Cells (ADMSCs)	Unknown	Injuries, Pain, and Autoimmune, Vascular and Other Disease, including Inflammatory lung conditions, pneumonia, and chronic obstructive pulmonary disease (COPD)	Celltex	Expanded access					Celltex press release Celltex

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
69	Ryonicil (remestemcel-L), allogenic mesenchymal stem cells	N/A		Mesoblast	Pre-clinical					FierceBiotech
70	MultiStem, bone marrow stem cells		Acute Respiratory Distress Syndrome; Stroke	Athersys	Clinical			Phase 2/3 trial to start 2Q 2020		BioSpace Athersys press release
71	Allogeneic T-cell therapies	N/A		AlloVir/Baylor College of Medicine	Pre-clinical					AlloVir FierceBiotech
72	Natural killer cell-based therapy	N/A		GC LabCell/KLEO Pharmaceuticals	Pre-clinical			Begin Phase 1 by end of 2020		UPI Korea Biomedical Review
73	CYNK-001, allogeneic, natural killer cell therapy	N/A	Various hematologic cancers and solid tumors	Celularity	Clinical			Phase 1/2 study to start in April 2020		Celularity press release
74	CAP-1002, allogenic cardiosphere-derived cells	N/A	Duchenne muscular dystrophy	Capricor Inc.	Expanded access		NCT04338347 (Capricor Inc.) (expanded access)			Capricor Therapeutics press release
75	haNK, natural killer cells	N/A		ImmunityBio/NantKwest	Pre-clinical					NantKwest and ImmunityBio press release
76	Bone marrow-derived allogenic mesenchymal stem cells (BM-Allo-MSK)	N/A		ImmunityBio/NantKwest	Pre-clinical					NantKwest and ImmunityBio press release
77	Allogenic, adipose-derived mesenchymal stem cells (HB-adMSCs)	N/A	Rheumatoid arthritis	Hope Biosciences	Clinical	Hope Biosciences Stem Cell Research Foundation	NCT04348435 (Hope Biosciences) (prevention) NCT04349631 (Hope Biosciences) (prevention)			Hope Biosciences press release
RNA-BASED TREATMENTS										
78	RNAi - testing 150 RNAs	N/A		Sirnaomics	Pre-clinical					NPR
79	siRNA candidates	N/A		Vir Biotech/Alnylam Pharmaceuticals	Pre-clinical					Clinical Trials Arena Celularity press release Vir and Alnylam press release
80	Ampligen; (rintatolimod)	N/A		AIM ImmunoTech/National Institute of Infectious Diseases in Japan	Pre-clinical					AIM Immunotech press release

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
81	OT-101, a TGF-Beta antisense drug candidate	N/A	Various cancers	Mateon Therapeutics	Clinical					Clinical Trials Arena Mateon Therapeutics
82	Inhaled mRNA	N/A		Neurimmune/Ethris	Pre-clinical			Phase 1 to start Q4 2020		Neurimmune
SCANNING COMPOUNDS TO REPURPOSE										
83	Scanning library of antiviral compounds	N/A	N/A	Janssen Pharmaceutical Companies	Pre-clinical	Biomedical Advanced Research and Development Authority (BARDA)				Johnson & Johnson PhRMA
84	Scanning compounds to repurpose	N/A	N/A	Novartis	Pre-clinical					PhRMA
85	Scanning antiviral compounds previously in development	N/A	N/A	Pfizer	Pre-clinical			Lead candidate (protease inhibitor) to start Phase 1 trial in Q3 2020		Pfizer PhRMA Pfizer
86	Scanning compounds to repurpose	N/A	N/A	Merck	Pre-clinical					Wall Street Journal
87	Repurposing antiviral drug candidates	N/A	N/A	Materia Medica/Cyclica	Pre-clinical					Cyclica press release
88	Screening new drugs + library of antiviral compounds	N/A	N/A	Enanta Pharmaceuticals	Pre-clinical					FierceBiotech Enanta Pharmaceuticals
89	Screening drug compounds	N/A	N/A	Southwest Research Institute	Pre-clinical					Clinical Trials Arena
90	Scanning compounds to repurpose	N/A	N/A	Takeda	Pre-clinical					PhRMA
91	Scanning compounds to repurpose	N/A	N/A	Queens University Belfast	Pre-clinical	UK Government				UK Government

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
92	Scanning compound libraries	N/A	N/A	COVID-19 Therapeutics Accelerator (15 companies shared their compound libraries including BD, bioMérieux, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Eli Lilly, Gilead, GSK, Johnson & Johnson, Merck [known as MSD outside the US and Canada], Merck KGaA, Novartis, Pfizer, and Sanofi)	Pre-clinical	Gates Foundation/ Wellcome/ Mastercard Impact Fund				Novartis press release Gates Foundation
93	Artificial intelligence-based screening to identify repurposed drug combinations		N/A	Healx	Pre-clinical			Combinations will be ready for preclinical testing in May 2020		Healx press releas
94	Identifying drugs to repurpose			The Castleman Disease Collaborative Network and the Center for Study & Treatment of Inflammatory Lymphadenopathies	Pre-clinical					Castleman Disease Collaborative Network

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
OTHERS										
95	Methylprednisolone / ciclesonide/ hydrocortisone/ corticosteroids	FDA-approved since at least the 1950s, approved to treat many diseases, including anti-inflammatory conditions and some cancers		Numerous trials with research sponsors globally; University of Oxford RECOVERY trial; REMAP-CAP global trial	Clinical	UK Government (University of Oxford RECOVERY trial)	NCT04244591 (Peking Union Medical College Hospital) (methylprednisolone) NCT04263402 (Tongji Hospital) (Methylprednisolone) NCT04273321 (Beijing Chao Yang Hospital) (Methylprednisolone) ChiCTR2000029656 (Wuhan Pulmonary Hospital) (methylprednisolone) ChiCTR2000029386 (Chongqing Public Health Medical Center) (Methylprednisolone) NCT02735707 (MJM Bonten) (REMAP-CAP global trial; hydrocortisone) NCT04330586 (Korea University Guro Hospital) (ciclesonide) 2020-001113-21 (RECOVERY Trial) (lopinavir-ritonavir; low-dose dexamethasone, hydroxychloroquine, azithromycin)	Primary study ends April 2020 (Peking) / June 2020 (Tongji)/ RECOVERY trial results expected by June 2020*	medRxiv medRxiv	World Health Organization UK Government REMAP-CAP REMAP-CAP RECOVERY Trial Endpoints News*

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
96	Chloroquine/ Hydroxychloroquine, antimalarial	FDA-approved since 1949, approved to treat malaria (chloroquine), FDA-approved since at least 1955, approved to treat malaria, rheumatoid arthritis, and lupus (hydroxychloroquine)		Numerous trials with global research sponsors; University of Minnesota; University of Washington/New York University (hydroxychloroquine); University of Oxford; IHU-Méditerranée Infection and others; World Health Organization SOLIDARITY trial (chloroquine); New York State Department of Health (hydroxychloroquine with zithromax); Mahidol Oxford Tropical Medicine Research Unit (hydroxychloroquine and chloroquine); ORCHID Trial with National Heart, Lung, and Blood Institute (NHLBI); REMAP-CAP global trial	Clinical / FDA issued an Emergency Use Authorization on March 28, 2020 (oral formulations of chloroquine phosphate and hdoxychloroquinine sulfate donated to the Strategic National Stockpile to treat adolescent and adult hospitalized patients with COVID-19 when a clinical trial is not available or feasible)	COVID-19 Treatment Accelerator (University of Washington/ New York University trial and Mahidol Oxford Tropical Medicine Research Unit trial); UK Government (University of Oxford RECOVERY trial)	NCT04261517 (Shanghai Public Health Clinical Center) (Hydroxychloroquine) NCT04303507 (University of Oxford) (chloroquine prevention study) NCT04303299 (Rajavithi Hospital) (Various combination of protease inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine) NCT04304053 (Fundacio Lluita Contra la SIDA) (prevention, darunavir/cobicistat or hydroxychloroquine) NCT04307693 (Asan Medical Center) (Lopinavir/Ritonavir or Hydroxychloroquine) NCT04316377 (University Hospital, Akershus) (Hydroxychloroquine) NCT04315948 (Institut National de la Santé Et de la Recherche Médicale, France) (remdesivir, lopinavir/ritonavir, interferon beta-1a, hydroxychloroquine) NCT04321993 (Lisa Barrett, Nova Scotia Health Authority) (lopinavir/ritonavir; hydroxychloroquine; baricitinib; sarilumab)	Results from the University of Washington/New York University trial expected in summer 2020; RECOVERY trial results expected by June 2020*	NCT04261517 (Shanghai Public Health Clinical Center) (Hydroxychloroquine) IHU-Méditerranée Infection Journal of ZheJiang University (Medical Sciences) medRxiv medRxiv medRxiv (ChiCTR2000029559) medRxiv medRxiv (NCT04323527) medRxiv medRxiv medRxiv medRxiv medRxiv ScienceDirect ISAC	World Health Organization BioCentury Endpoints News Stat News Politico Sandoz University of Washington Mastercard press release FDA RECOVERY Trial Endpoints News*

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
96 (cont.)	Chloroquine/ Hydroxychloroquine, antimalarial						2020-001113-21 (RECOVERY Trial) (lopinavir-ritonavir; low-dose dexamethasone, hydroxychloroquine, azithromycin) NCT04323527 (Fundação de Medicina Tropical Dr. Heitor Vieira Dourado) NCT04333732 (Washington University School of Medicine) NCT04332991 (Massachusetts General Hospital) (ORCHID trial, National Heart, Lung, and Blood Institute [NHLBI]) NCT04345419 (Tanta University) (chloroquine; favipiravir; nitazoxanide; ivermectin; niclosamide) NCT04341870 (Assistance Publique - Hôpitaux de Paris) (sarilumab, azithromycin, hydroxychloroquine; CORIMUNO-VIRO trial) NCT04345289 (Thomas Benfield, Hvidovre University Hospital) (convalescent anti-SARS-CoV-2 plasma; sarilumab; baricitinib; hydroxychloroquine) NCT02735707 (MJM Bonten, UMC Utrecht) (REMAP-CAP trial) Over 22 trials registered in China		ScienceDirect medRxiv medRxiv (ChiCTR2000029868)	

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
97	Camostat mesylate, transmembrane protease serine 2 (TMPRSS2) inhibitor, approved in Japan to treat multiple conditions including pancreatitis	N/A		Leibniz Institute for Primate Research/University Göttingen and others	Clinical		NCT04321096 (University of Aarhus)			Nature Biotechnology bioRxiv Thailand Medical News Cell
98	Jakafi/jakavi (ruxolitinib)	FDA-approved since 2011, approved to treat myelofibrosis, polycythemia vera, and acute graft-versus-host disease		Novartis /Incyte, Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology/Incyte Corp	Clinical / Expanded Acces		ChiCTR2000029580 (Department of Hematology, Tongji Medical College, Huazhong University of Science and Technology) (ruxolitinib in combination with mesenchymal stem cells) NCT04334044 (Grupo Cooperativo de Hemopatías Malignas) NCT04331665 (University Health Network, Toronto) NCT04337359 (Novartis Pharmaceuticals) (Expanded Access)			World Health Organization Novartis Incyte press release

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
99	PegIntron, Sylatron, IntronA (peginterferon alfa-2b)	PegIntron - FDA-approved since 2001, approved to treat Hepatitis C; Sylatron - FDA-approved since 2001, approved for the adjuvant treatment of melanoma; Intron A - FDA-approved since 1986, approved to treat Hepatitis C and certain cancers		Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital) (Schering)	Clinical					World Health Organization
100	Novaferon, Nova, interferon, licensed in China for Hepatitis B	N/A		The First Affiliated Hospital of Zhejiang University Medical School	Clinical		ChiCTR2000029573 (The First Affiliated Hospital of Medical College of Zhejiang University) (antiviral therapy, Chinese medicine treatment, and Novaferon atomization) ChiCTR2000029496 (Hu'nan Haiyao hongxingtang Pharmaceutical Co., Ltd) (Novaferon, Kaletra, Novaferon+Kaletra)			World Health Organization
101	Traumakine (interferon beta 1-a)	N/A		Faron Pharmaceuticals/REMAP-CAP global trial	Clinical		NCT02735707 (MJM Bonten) (REMAP-CAP global trial)	Added to REMAP-CAP trial		Faron Pharmaceuticals press release
102*	Recombinant human interferon alpha-1b*			Shanghai Jiao Tong University School of Medicine*	Clinical*		NCT04320238 (Shanghai Jiao Tong University School of Medicine) (prevention)*		medRxiv*	
103*	SNG001, inhaled formulation of interferon beta-1a	N/A	Asthma patients with cold or flu infection; COPD patients with viral infections	Synairgen / University of Southampton	Clinical			Phase 2 began in March 2020		pharmaphorum
104*	Peginterferon lambda		Hepatitis Delta	Eiger BioPharmaceuticals, Inc.	Clinical		NCT04331899 (Stanford University)	Phase 2 began in April 2020		Eiger BioPharmaceuticals press release Eiger BioPharmaceuticals

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
105*	Cerocal (ifenprodil), NP-120, an NDMA receptor glutamate receptor antagonist targeting Glu2NB	N/A	Idiopathic Pulmonary Fibrosis	Algernon Pharmaceuticals	Pre-clinical					Clinical Trials Arena Algernon Pharmaceuticals
106*	APN01; recombinant soluble human Angiotensin Converting Enzyme 2	N/A	Acute lung injury, Acute respiratory distress syndrome, Pulmonary arterial hypertension	University of British Columbia/ Apeiron Biologics	Clinical	Austrian Government		Phase 2 began in April 2020		Clinical Trials Arena Apeiron Biologics Apeiron Biologics press release
107*	Brilacidin, a defensin mimetic	N/A	Oral Mucositis; Ulcerative Proctitis/Ulcerative Proctosigmoiditis; Acute Bacterial Skin and SkiWn Structure Infection	Innovation Pharmaceuticals	Clinical					Clinical Trials Arena Innovation Pharmaceuticals Innovation Pharmaceuticals
108*	BXT-25; glycoprotein	N/A		Bioxytran	Pre-clinical					Clinical Trials Arena
109*	Peptides targeting the NP protein	Unknown		CEL-SCI/University of Georgia Center for Vaccines and Immunology	Pre-clinical					Clinical Trials Arena CEL-SCI Corporation press release FierceBiotech BioSpace
110*	BIO-11006, inhaled peptide	N/A	Acute Respiratory Distress Syndrome; Non-Small Cell Lung Cancer; Chronic Obstructive Pulmonary Disease (COPD)	Biomarck Pharmaceuticals	Clinical					Biomarck Pharmaceuticals
111*	Gilenya (fingolimod), sphingosine 1-phosphate receptor modulator	FDA-approved since 2010, approved to treat multiple sclerosis		The First Affiliated Hospital of Fujian Medical University/Novartis	Clinical		NCT04280588 (First Affiliated Hospital of Fujian Medical University)	Primary trial ends July 2020		
112*	WP1122, glucose decoy prodrug (and related drug candidates)	N/A		Moleculin Biotech/University of Texas Medical Branch	Pre-clinical					FierceBiotech Moleculin

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
113*	Rebif (interferon beta-1a)	FDA-approved since 2002, approved to treat multiple sclerosis		Institut National de la Sante et de la Recherche Medicale (Merck KGaA)	Clinical		EudraCT 2020-000936-23, INSERM study (lopinavir/ritonavir; Rebif; remdesivir) NCT04315948 (Institut National de la Santé Et de la Recherche Médicale, France) (remdesivir, lopinavir/ritonavir, interferon beta-1a, hydroxychloroquine)			Merck KGaA press release
114*	nafamostat, approved in Japan to treat pancreatitis and other diseases	N/A		University of Tokyo/National Center for Global Health and Medicine/ Ensysce Biosciences	Clinical			University of Tokyo trial (IV formulation) starts April 2020; Ensysce trial will be with oral formulation		Bloomberg News Ensysce press release
115*	A number of synthesized nanoviricide drug candidates	N/A		NanoViricides	Pre-clinical					Clinical Trials Arena NanoViricides Inc.
116*	losartan	FDA-approved since 1995, approved to treat hypertension and diabetic nephropathy		University of Minnesota	Clinical		NCT04312009 (University of Minnesota) (Losartan for Patients With COVID-19 Requiring Hospitalization) NCT04311177 (University of Minnesota) (Losartan for Patients With COVID-19 Not Requiring Hospitalization)			KARE TV
117*	Activase (alteplase), tissue plasminogen activator (tPA)	FDA-approved since 1987, approved to treat stroke, myocardial infarction, and pulmonary embolism		Beth Israel Deaconess, the University of Colorado Anschutz Medical Campus, and Denver Health (Genentech)	Compassionate Use					MIT News

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
118*	Leukine (sargramostim, rhu-Granulocyte macrophage colony stimulating factor)	FDA-approved since 1991, approved to shorten the time to neutrophil recovery and reduce the incidence of infections following chemotherapy, mobilize hematopoietic progenitor cells, accelerate myeloid reconstitution following bone marrow or cell transplantation, treat delayed neutrophil recovery or graft failure after bone marrow transplantation, and increase survival of radiation	Pulmonary conditions that affect alveolar macrophages (nebulized leukine); ARDS (IV leukine)	Partner Therapeutics	Clinical		NCT04326920 (University Hospital, Ghent)			Partner Therapeutics
119*	Kineret (anakinra), interleukin-1 receptor antagonist	FDA-approved since 2001, approved to treat rheumatoid arthritis and cryopyrin-associated periodic syndromes		Swedish Orphan Biovitrum/REMAP-CAP global trial	Clinical		NCT04324021 (Swedish Orphan Biovitrum) (Emapalumab; Anakinra) NCT02735707 (MJM Bonten) (REMAP-CAP global trial)			REMAP-CAP
120*	AT-001, aldose reductase inhibitor	N/A	Diabetic cardiomyopathy	Applied Therapeutics / numerous New York City hospitals	Clinical / Compassionate Use					Applied Therapeutics
121*	Aplidin (plitidepsin), approved in Australia to treat multiple myeloma			PharmaMar	Clinical					PharmaMar
122*	dipyridamole (Persantine), anticoagulant	FDA-approved since 1961, approved to prevent postoperative thromboembolic complications of cardiac valve replacement		Numerous Chinese hospitals	Clinical				medRxiv	

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
123*	recombinant human plasma gelsolin (rhu-pGSN)	N/A	Community-acquired pneumonia	BioAegis Therapeutics Inc.	Clinical					GlobeNewswire
124*	solnatide (synthetic molecule with a structure based on the lectin-like domain of human Tumour Necrosis Factor alpha)	N/A	Pneumonia, sepsis, ARDS, Primary Graft Dysfunction, and pulmonary dysfunctions	Apeptico	Clinical	EU Commission (Horizon 2020 Program)				APEPTICO
125*	Nitric oxide	FDA-approved since 1999, approved to improve oxygenation in neonates		Massachusetts General Hospital; University of British Columbia	Clinical		NCT04305457 (Massachusetts General Hospital) NCT04312243 (Massachusetts General Hospital) (prevention) NCT04306393 (Massachusetts General Hospital) NCT03331445 (University of British Columbia)			Newsweek
126*	PP-001	N/A	Severe eye diseases	Panoptes Pharma GmbH	Clinical					LISAvienna
127*	ARMS-1	N/A	Influenza prophylaxis	ARMS Pharmaceutical/UH Cleveland Medical Center/Case Western Reserve University	Clinical	Cleveland Foundation		Trial starts April 2020		University Hospitals press release
128*	PUL-042 inhalation solution	N/A	Prevent and treat respiratory complications in immunosuppressed cancer patients	Pulmotect	Clinical		NCT04312997 (Pulmotect, Inc.)			Pulmotect

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
129*	Olumiant (baricitinib), Janus kinase (JAK) inhibitor	FDA-approved since 2018, approved to treat rheumatoid arthritis		National Institute of Allergy and Infectious Disease (NIAID)'s Adaptive COVID-19 Treatment Trial; Nova Scotia Health Authority; Hospital of Prato; University of Colorado (Eli Lilly)	Clinical		NCT04321993 (Lisa Barrett, Nova Scotia Health Authority) (lopinavir/ritonavir; hydroxychloroquine; baricitinib; sarilumab) NCT04320277 (Hospital of Prato) NCT04340232 (University of Colorado, Denver) NCT04280705 (National Institute of Allergy and Infectious Diseases [NIAID]) (Adaptive COVID-19 Treatment Trial [ACTT]) NCT04345289 (Thomas Benfield, Hvidovre University Hospital) (convalescent anti-SARS-CoV-2 plasma; sarilumab; baricitinib; hydroxychloroquine)			Eli Lilly
130*	Xeljanz (tofacitinib), Janus kinase (JAK) inhibitor	FDA-approved since 2012, approved to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis		Pfizer	Clinical		NCT04332042 (Università Politecnica delle Marche)			Pfizer

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
131*	colchicine	N/A (but has been used in the US since the early 1800s, and FDA-approved in combination with probenecid, approved to treat gout)		Numerous research sponsors globally	Clinical		NCT04326790 (National and Kapodistrian University of Athens) NCT04328480 (Estudios Clínicos Latino América) NCT04322565 (Lucio Manenti, Azienda Ospedaliero-Universitaria di Parma) NCT04322682 (Montreal Heart Institute)			National Post
132*	low molecular weight heparin, anticoagulant	FDA-approved since at least 1993, approved to prevent blood clots and prevent/treat venous thromboembolism and myocardial infarction		Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Clinical					medRxiv
133*	LAU-7b (fenretinide)	N/A	Treat exaggerated inflammatory response in adult cystic fibrosis patients	Laurent Pharmaceuticals	Clinical			Phase 2 to start May 2020		Laurent Pharmaceuticals press release
134*	Xpovio (selinexor), oral, selective inhibitor of nuclear export (SINE) compound	FDA-approved since 2019, approved to treat multiple myeloma	Treat various cancers	Karyopharm Therapeutics	Clinical					Karyopharm Therapeutics Komodo Health press release
135*	BLD-2660, synthetic small molecule inhibitor of calpain (CAPN) 1, 2, and 9	N/A		Blade Therapeutics	Clinical		NCT04334460 (Blade Therapeutics)			
136*	Calquence (acalabrutinib), Bruton's tyrosine kinase (BTK) inhibitor	FDA-approved since 2017, approved to treat mantle cell lymphoma and chronic lymphocytic leukemia		AstraZeneca	Clinical					AstraZeneca

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
137*	CD24Fc, biological immunomodulator (nonpolymorphic regions of CD24 attached to the Fc region of human IgG1)	N/A	Graft versus Host Disease	Oncolmune	Clinical			Phase 3 trial to start in April		Oncolmune press release
138*	Aviptadil, synthetic form of Vasoactive Intestinal Polypeptide	N/A	Sarcoid, Pulmonary Fibrosis, Bronchospasm, Erectile Dysfunction, and Acute Respiratory Distress Syndrome (ARDS)	NeuroRx/Relief Therapeutics/Thomas Jefferson University Hospital	Clinical			Phase 2 trial started in April 2020		NeuroRx Relief Therapeutics press release
139*	vazegapant, CGRP receptor antagonist		Acute migraine	Biohaven/Thomas Jefferson University	Clinical			Phase 2 to start April 2020		Biohaven Pharmaceuticals Endpoints News
140*	CM4620-IE, calcium release-activated calcium (CRAC) channel inhibitor		Pancreatitis	CalciMedica	Clinical			Phase 2 started in April 2020		Endpoints News CalciMedica
141*	ivermectin	FDA-approved since 1996, approved to treat intestinal parasites and head lice infestations		University of Utah/Surgisphere Corp; University of Baghdad; Tanta University	Clinical		NCT04343092 (University of Baghdad) NCT04345419 (Tanta University) (chloroquine; favipiravir; nitazoxanide; ivermectin; niclosamide)			SSRN
142*	EPAAspire, oral formulation of highly purified eicosapentaenoic acid free fatty acid (EPA-FFA) in gastro-resistant capsules	N/A	Familial adenomatous polyposis	KD Pharma/SLA Pharma	Clinical					KD Pharma Group and SLA Pharma press release
143*	niclosamide	N/A	Atopic Dermatitis	Union Therapeutics/Institut Pasteur Korea	Clinical		NCT04345419 (Tanta University) (chloroquine; favipiravir; nitazoxanide; ivermectin; niclosamide)			UNION Therapeutics press release
144*	ADX-629, orally available reactive aldehyde species (RASP) inhibitor	N/A	Systemic immune-mediated diseases	Aldeyra Therapeutics	Clinical					Aldeyra press release

* Indicates updated or new field

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
145*	N-803, IL-15 "superagonist"	N/A	Bladder Carcinoma In Situ	ImmunityBio/NantKwest	Clinical					NantKwest and ImmunityBio press release
146*	piclidenoson, A3 adenosine receptor agonist	N/A	Rheumatoid arthritis; psoriasis	Can-Fite BioPharma	Clinical		NCT04333472 (Can-Fite BioPharma)			Can-Fite BioPharma press release
DEVICES										
147*	CytoSorb (blood purification device, extracorporeal cytokine adsorber)	N/A		CytoSorbents Corporation	FDA issued an Emergency Use Authorization on April 10, 2020/Clinical/Compassionate Use		NCT04324528 (Dr. Alexander Supady) ChiCTR2000030475 (Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College)		NCT04344080 (Universitätsklinikum Hamburg-Eppendorf)	CytoSorbents Corporation press release FDA
148*	Extracorporeal blood purification (EBP) devices			Terumo BCT Inc/Marker Therapeutics AG	FDA issued an Emergency Use Authorization on April 9, 2020					FDA
149*	Seraph100MicrobindAffinity Blood Filter (Seraphy 100), approved in the EU for pathogen reduction	N/A		ExThera Medical	Clinical					ExThera press release
150*	INOpulse			Bellerophon	Compassionate Use					Bellerophon Therapeutics
DORMANT/DISCONTINUED										
1	Washed microbiota transplantation	Unknown		The Second Hospital of Nanjing Medical University	Clinical		NCT04251767 (The Second Hospital of Nanjing Medical University) (Washed Microbiota Transplantation for Patients With 2019-nCoV Infection)		Study stopped before recruitment	BioCentury

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
2	Recombinant ACE2 (angiotensin-converting enzyme 2)	Unknown		The First Affiliated Hospital of Guangzhou Medical University	Clinical		NCT04287686 (The First Affiliated Hospital of Guangzhou Medical University) (Recombinant Human Angiotensin-converting Enzyme 2 [rhACE2] as a Treatment for Patients With COVID-19)		Study stopped before recruitment	BioCentury Applied DNA press release

COVID-19 Treatment and Vaccine Tracker

This document contains an aggregation of publicly available information from validated sources. It is not an endorsement of one approach or treatment over another, but simply a list of all treatments and vaccines currently in development.

VACCINES

Number	Type of Vaccine	Related Use/Platform	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
1	DNA plasmid; INO-4800	Same platform as vaccine candidates for Lassa, Nipah, HIV, Filovirus, HPV, cancer indications, Zika, and Hepatitis B	Inovio Pharmaceuticals/Beijing Advaccine Biotechnology	Clinical	Coalition for Epidemic Preparedness (CEPI)/Gates Foundation	NCT04336410 (Inovio Pharmaceuticals)	Started Phase 1 April 2020; initial data expected late summer 2020		World Health Organization MarketWatch BioAegis Therapeutics INOVIO
2	DNA		Takis/Applied DNA Sciences/Evvivax	Pre-clinical			Preclinical results expected in April 2020; Phase 1 to start in fall 2020		World Health Organization Takis Applied DNA press release
3	DNA plasmid		OPENCORONA - Cobra Biologics/Karolinska Institute	Pre-clinical	European Commission (Horizon 2020 Program)		Phase 1 to start in 2020		BioSpace
4	DNA plasmid		Osaka University/AnGes/Takara Bio	Pre-clinical					World Health Organization
5	DNA plasmid		Zydus Cadila	Pre-clinical					World Health Organization
6	DNA plasmid, needle-free delivery	Same platform as vaccine candidates for SARS	Immunomic Therapeutics/EpiVax/PharmaJet	Pre-clinical					World Health Organization Immunomic Therapeutics press release
7*	DNA*		BioNet Asia*	Pre-clinical*					World Health Organization*
8*	DNA*		University of Waterloo*	Pre-clinical*					World Health Organization*

LEGEND

CCHF = Crimean-Congo Haemorrhagic Fever	HIV = Human Immunodeficiency Virus	NIPV = Nipah Virus	TB = Tuberculosis
CHIKV = Chikungunya Virus	HPV = Human Papilloma Virus	NORV = Norovirus	VEE = Venezuelan Equine Encephalitis Virus
DengV = Dengue Virus	Inf = Influenza	RABV = Rabies Virus	VZV = Varicella Vaccine (Chickenpox)
FMD = Foot and Mouth Disease	LASV = Lassa Fever Virus	RSV = Respiratory Syncytial Virus	YFV = Yellow Fever Virus
EBOV = Ebola Virus	MARV = Marburg Virus	RVF = Rift Valley Fever	ZIKV = Zika Virus
HAV = Hepatitis A Virus	MenB = Meningitis B	SARS = Severe Acute Respiratory Syndrome	
HBV = Hepatitis B Virus	MERS = Middle East Respiratory Syndrome	SIV = Simian Immunodeficiency Virus	

* Indicates updated or new field

Number	Type of Vaccine	Related Use/Platform	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
9*	Inactivated (inactivated + CpG 1018)*	Same platform as vaccine candidates for SARS	Sinovac/Dynavax	Pre-clinical			Phase 1 to start in April 2020		World Health Organization Sinovac press release Dynavax and Sinovac press release World Health Organization*
10*	Inactivated		Beijing Institute of Biological Products/Wuhan Institute of Biological Products	Clinical*		ChiCTR2000031809 (Wuhan Institute of Biological Products Co., Ltd.)*	Phase 1 to start in April 2020*		World Health Organization World Health Organization*
11*	Inactivated		Osaka University/BIKEN/NIBIOHN	Pre-clinical					World Health Organization
12*	Deoptimized live attenuated virus	Same platform as vaccine candidates for HAV, InfA, ZIKV, FMD, SIV, RSV, DENV	Codagenix/Serum Institute of India	Pre-clinical			Animal data in summer 2020		World Health Organization Indian Express
13*	CoroFlu, self-limiting influenza virus	Same platform as vaccine candidates for influenza	University of Wisconsin-Madison / FluGen/ Bharat Biotech	Pre-clinical			Start Phase 1 trial in fall 2020		Press release from the collaboration
14*	Non-replicating viral vector; MVA encoded VLP	Same platform as vaccine candidates for LASV, EBOV, MARV, HIV	GeoVax/BravoVax	Pre-clinical					World Health Organization GeoVax GeoVax
15*	Non-replicating viral vector; Ad26 (alone or with MVA boost)	Same platform as vaccine candidates for Ebola, HIV, RSV	Janssen Pharmaceutical Companies/ Beth Israel Deaconess Medical Center	Pre-clinical	Biomedical Advanced Research and Development Authority (BARDA)		Start Phase 1 in September 2020		World Health Organization Johnson & Johnson Johnson & Johnson FierceBiotech Johnson & Johnson press release
16*	Non-replicating viral vector; replication defective simian adenovirus (GRAd) encoding SARS-CoV-2 S*		ReiThera*	Pre-clinical*					World Health Organization*
17*	Non-replicating viral vector; Ad5		ImmunityBio/NantKwest	Pre-clinical					NantKwest and ImmunityBio press release

Number	Type of Vaccine	Related Use/Platform	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
18*	Non-replicating viral vector; ChAdOx1	Same platform as vaccine candidates for influenza, TB, Chikungunya, Zika, MenB, plague	Consortium of the Jenner Institute, Oxford Biomedica, University of Oxford, Vaccines Manufacturing and Innovation Centre, Pall Life Sciences, Cobra Biologics, HalixBV, Advent s.r.l., and Merck KGaA*	Clinical	Coalition for Epidemic Preparedness (CEPI)/UK Government	NCT04324606 (University of Oxford)	Animal trials begin March 2020, Phase 1 begins April 2020		World Health Organization Guardian Fierce Biotech World Health Organization PharmaTimes BioCentury*
19*	Non-replicating viral vector; MVA-S encoded*	Same platform as vaccine candidates for many pathogens	DZIF - German Center for Infection Research	Pre-clinical					World Health Organization
20*	AdCOVID; single-dose, intranasal vaccine; non replicating viral vector; adenovirus-based NasoVAX expressing spike protein	Same platform as vaccine candidates for influenza	Altimune/University of Alabama at Birmingham	Pre-clinical			Phase 1 trial to begin Q3 2020		World Health Organization Altimune press release Altimune
21*	Non-replicating viral vector; Ad5 S (GREVAX™ platform)	Same platform as vaccine candidates for MERS	Greffex	Pre-clinical					World Health Organization Greffex
22*	Non-replicating viral vector; Oral Vaccine platform	Same platform as vaccine candidates for InfA, CHIKV, LASV, NORV, EBOV, RVF, HBV, VEE	Vaxart/Emergent BioSolutions	Pre-clinical			Phase 1 trial to begin in the second half of 2020		World Health Organization Vaxart press release Emergent BioSolutions
23*	Non-replicating viral vector, MVA expressing structural proteins	Same platform as vaccine candidates for HIV, HCV, CHIKV, EBOV, Zika, Malaria, Leishmania	Centro Nacional Biotecnologia (CNB-CSIC), Spain	Pre-clinical					World Health Organization
24*	Non-replicating viral vector; dendritic cell-based vaccine*		University of Manitoba*	Pre-clinical*					World Health Organization*

Number	Type of Vaccine	Related Use/Platform	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
25*	Non-replicating viral vector; Adenovirus Type 5 vector (Ad5-nCoV)	Same platform as vaccine candidates for EBOV	CanSino Biologics/Beijing Institute of Biotechnology	Clinical		NCT04313127 (CanSino Biologics Inc.)	Phase 2 started April 2020	ChiCTR2000030906 (Insitute of Biotechnology, Academy of Military Medical Sciences, PLA of China) (Phase 1) ChiCTR2000031781 (Insitute of Biotechnology, Academy of Military Medical Sciences, PLA of China) (Phase 2)	World Health Organization FiercePharma CanSino Biologics announcement Xinhua
26*	Protein subunit, capsid-lide particle (CLP)	Same platform as vaccine candidates for HPV	PREVENT-nCoV consortium (AdaptVac, Institute for Tropical Medicine at University of Tubingen, Leiden University Medical Center, University of Copenhagen, ExpreS2ion Biotechnologies, Wageningen University)	Pre-clinical	European Commission (Horizon 2020 Program)		Phase 1 to begin by February 2021		AdaptVac World Health Organization ExpreS2ion press release
27*	Protein subunit, drosophila S2 insect cell expression system VLPs		ExpreS2ion	Pre-clinical					World Health Organization
28*	Protein subunit; S protein		WRAIR/USAMRIID	Pre-clinical					World Health Organization
29*	Protein subunit, S protein + adjuvant	Same platform as vaccine candidates for Influenza	National Institute of Infectious Disease, Japan	Pre-clinical					World Health Organization
30*	Protein subunit, VLP-recombinant protein + adjuvant		Osaka University/BIKEN/National Institutes of Biomedical Innovation, Japan	Pre-clinical					World Health Organization
31*	Protein subunit, native like trimeric subunit spike protein	Same platform as vaccine candidates for HIV, RSV, Influenza	Clover Biopharmaceuticals Inc./GSK/Dynavax	Pre-clinical					World Health Organization World Health Organization

* Indicates updated or new field

Number	Type of Vaccine	Related Use/Platform	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
32*	Protein subunit; peptide		Vaxil Bio	Pre-clinical					World Health Organization
33*	Protein subunit; adjuvanted protein subunit (RBD)		Biological E Ltd	Pre-clinical					World Health Organization
34*	Protein subunit; S protein		AJ Vaccines	Pre-clinical					World Health Organization
35*	Protein subunit; S protein		Vaxine Pty Ltd/ Flinders University / Oracle	Pre-clinical					Flinders University press release
36*	Protein subunit; li-Key peptide	Same platform as vaccine candidates for HIV, SARS-CoV, Influenza	Generex/EpiVax	Pre-clinical					World Health Organization Generex press release EpiVax
37*	Protein subunit; S protein	Same platform as vaccine candidates for Inf H7N9	EpiVax/University of Georgia	Pre-clinical					World Health Organization EpiVax
38*	PittCoVacc, Protein subunit, microneedle arrays S1 subunit	Same platform as vaccine candidates for MERS	University of Pittsburgh	Pre-clinical			Phase 1 to start as early as June 2020		University of Pittsburgh press release EBioMedicine World Health Organization
39*	Protein subunit; S protein	Influenza, Ebola	University of Cambridge/DIOSynVax	Pre-clinical			Phase 1 to start as early as June 2020		University of Cambridge
40*	Protein subunit; COVID-19 XWG-03 truncated Spike proteins	Same platform as vaccine candidates for HPV	Innovax/Xiamen University/GSK	Pre-clinical					FierceBiotech World Health Organization
41*	Protein subunit; S protein, baculovirus production	Same platform as vaccine candidates for Influenza, SARS-CoV (FDA-approved vaccine)	Sanofi Pasteur/GSK	Pre-clinical	Biomedical Advanced Research and Development Authority (BARDA)		Start Phase 1 in second half of 2020		World Health Organization Sanofi Stat News MarketWatch Sanofi
42*	NVX-CoV2373; Protein subunit; Full length S trimers/nanoparticle + Matrix M	Same platform as vaccine candidates for RSV, CCHF, HPV, VZV, EBOV	Novavax/Emergent BioSolutions	Pre-clinical	Coalition for Epidemic Preparedness (CEPI)		Start Phase 1 in May 2020		World Health Organization Emergent BioSolutions Endpoints News
43*	Protein subunit (gp-96 backbone)	Same platform as vaccine candidates for cancer (NSCLC), HIV, malaria, Zika	Heat Biologics (Zolovax) /University of Miami	Pre-clinical					World Health Organization Clinical Trials Arena Heat Biologics

Number	Type of Vaccine	Related Use/Platform	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
44*	Protein subunit; molecular clamp stabilized Spike protein	Same platform as vaccine candidates for Nipah, influenza, Ebola, Lassa	University of Queensland/GSK/Dynavax	Pre-clinical	Coalition for Epidemic Preparedness (CEPI)/ Queensland Government/ Federal Government (Australia)/Paul Ramsay Foundation				World Health Organization ABC News Australia Dynavax World Health Organization
45*	Protein subunit; S1 or RBD protein	Same platform as vaccine candidates for SARS	Baylor College of Medicine	Pre-clinical					World Health Organization
46*	Protein subunit; Subunit protein, plant produced		iBio/CC-Pharming	Pre-clinical					World Health Organization
47*	Protein subunit, recombinant protein, nanoparticles (based on S-protein and other epitopes)		St. Petersburg Scientific Research Institute of Vaccines and Serums	Pre-clinical					World Health Organization
48*	Protein subunit, adjuvanted microsphere peptide		VIDO-InterVac, University of Saskatchewan	Pre-clinical	The Government of Saskatchewan and the Canadian Federal Government		Animal testing results expected in April 2020		World Health Organization World Health Organization Government of Saskatchewan
49*	Protein subunit, peptide	Same platform as vaccine candidates for Ebola, Marburg, HIV, Zika, Influenza, HPV therapeutic vaccine, Breast Cancer	Flow Pharma	Pre-clinical					World Health Organization
50*	Protein subunit, synthetic long peptide vaccine candidate for S and M proteins		OncoGen	Pre-clinical					World Health Organization
51*	Protein subunit; oral E. coli-based protein expression system of S and N proteins*		MIGAL Galilee Research Institute*	Pre-clinical*					World Health Organization*
52*	Protein subunit; spike based*	Same platform as vaccine candidates for Hepatitis C*	University of Alberta*	Pre-clinical*					World Health Organization*

Number	Type of Vaccine	Related Use/Platform	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
53*	DPX-COVID-19, protein subunit, lipid-based delivery platform	Same platform as vaccine candidates for cancer and infectious diseases, including malaria and anthrax	IMV, Inc. / Canadian Center for Vaccinology at Dalhousie University/ Izaak Walton Killam Health Center/ Nova Scotia Health Authority; Canadian Immunization Research Network / University of Laval / Global Urgent and Advanced Research and Development in Canada	Pre-clinical			Start Phase 1 testing by summer 2020		IMV, Inc. IMV, Inc.
54*	Pan-coronavirus vaccine candidate, targeting COVID-19, SARS, and MERS, spike protein		VBI Vaccines / National Research Council of Canada	Pre-clinical			Start Phase 1 testing by end of 2020		VBI Vaccines press release
55*	Replicating viral vector; measles vector		Zydus Cadila	Pre-clinical					World Health Organization
56*	Replicating viral vector; measles vector	Same platform as vaccine candidates for West Nile, CHIKV, Ebola, Lassa, Zika, MERS	Institut Pasteur/Themis/University of Pittsburgh	Pre-clinical	Coalition for Epidemic Preparedness (CEPI)		Start animal testing in April 2020		World Health Organization University of Pittsburgh Medical Center Coalition for Epidemic Preparedness
57*	Live attenuated virus, measles virus (S, N targets)*	Same platform as vaccine candidates for Zika, H7N9, CHIKV	DZIF - German Center for Infection Research	Pre-clinical					World Health Organization
58*	Replicating viral vector; horsepox vector; TNX-1800	Same platform as vaccine candidates for smallpox, monkeypox	Tonix Pharma/Southern Research	Pre-clinical					World Health Organization Tonix Pharmaceuticals press release
59*	Replicating viral vector, live viral vectored vaccine based on attenuated influenza virus backbone (intranasal)		BIOCAD/IEM	Pre-clinical					World Health Organization
60*	Replicating viral vector, VSV vector expressing S protein	Same platform as vaccine candidates for Ebola, Marburg, Lassa	IAVI/ Batavia	Pre-clinical					World Health Organization
61*	Replicating viral vector, influenza vector expressing RBD*	Same platform as vaccine candidates for MERS*	The University of Hong Kong*	Pre-clinical*	Coalition for Epidemic Preparedness (CEPI)*				World Health Organization* Coalition for Epidemic Preparedness*
62*	Replicating viral vector; VSV-S*	Same platform as vaccine candidates for HIV, MERS*	University of Western Ontario*	Pre-clinical*					World Health Organization*

* Indicates updated or new field

Number	Type of Vaccine	Related Use/Platform	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
63*	RNA; LNP-encapsulated mRNA cocktail encoding VLP		Fudan University/Shanghai JiaoTong University/RNACure Biopharma	Pre-clinical					World Health Organization
64*	RNA; LNP-encapsulated mRNA cocktail encoding RBD		Fudan University/Shanghai JiaoTong University/RNACure Biopharma	Pre-clinical					World Health Organization
65*	RNA; Replicating defective SARS-CoV-2 derived RNAs		Centro Nacional Biotecnologia (CNB-CSIC), Spain	Pre-clinical					World Health Organization
66*	RNA; LNP-encapsulated mRNA	Same platform as vaccine candidates for MERS	University of Tokyo/ Daiichi-Sankyo	Pre-clinical					World Health Organization
67*	RNA; mRNA		China CDC/Tongji University/Stermina	Pre-clinical					World Health Organization
68*	RNA; LNP-encapsulated mRNA (mRNA 1273)	Same platform as vaccine candidates for multiple candidates	Moderna/NIAID	Clinical	Coalition for Epidemic Preparedness (CEPI)/ Biomedical Advanced Research and Development Authority (BARDA)	NCT04283461 (National Institute of Allergy and Infectious Diseases)	Phase 1 started March 2020, study ends June 2021		World Health Organization Wall Street Journal MarketWatch ClinicalTrials.gov
69*	LUNAR-COV19; RNA; mRNA	Same platform as vaccine candidates for multiple candidates	Arcturus/Duke-NUS	Pre-clinical			Start Phase 1 in summer 2020		World Health Organization Arcturus Therapeutics Arcturus Therapeutics
70*	RNA; saRNA	Same platform as vaccine candidates for EBOV, LASV, MARV, Inf (H7N9), RABV	Imperial College London	Pre-clinical			Start Phase 1 in summer 2020		World Health Organization Imperial College London
71*	RNA; mRNA	Same platform as vaccine candidates for RABV, LASV, YFV, MERS, InfA, ZIKV, DengV, NIPV	CureVac	Pre-clinical	Coalition for Epidemic Preparedness (CEPI); European Commission		Start Phase 1 in June 2020		World Health Organization Labiotech.eu
72*	RNA; BNT162		BioNTech/Fosun Pharma/Pfizer	Pre-clinical			Start Phase 1 late April 2020		FierceBiotech Endpoints News World Health Organization Pfizer and BioNTech press release
73*	RNA; liposome-encapsulated mRNA	Same platform as vaccine candidates for cancer	BIOCAD	Pre-clinical			Animal studies begin in April 2020		BIOCAD

* Indicates updated or new field

Number	Type of Vaccine	Related Use/Platform	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
74*	RNA; mRNA		Sanofi Pasteur/ Translate Bio	Pre-clinical					Translate Bio
75*	RNA; mRNA (cross-strain protective COV-2 mRNA) vaccine for high-risk populations		eTheRNA Immunotherapies/EpiVax/ Nexelis/REPROCELL/Centre for the Evaluation of Vaccination of the University of Antwerp	Pre-clinical			Start Phase 1 early 2021		EpiVax
76*	RNA		GeneOne Life Science/Houston Methodist	Pre-clinical					Houston Methodist
77*	VLP; virus-like particle, based on RBD displayed on virus-like particle		Saiba GmbH	Pre-clinical					World Health Organization
78*	VLP; plant-derived VLP	Same platform as vaccine candidates for flu, rotavirus, norovirus, West Nile virus, and cancer	Medicago Inc.	Pre-clinical			Start Phase 1 in July/ August 2020		World Health Organization Medicago press release
79*	VLP; ADDomer™ multiepitope display		Imphoron Ltd/Bristol University's Max Planck Centre	Pre-clinical					World Health Organization University of Bristol
80*	VLP*		Doherty Institute*	Pre-clinical*					World Health Organization*
81*	Gene-encoded antibody vaccine, non-viral nanoparticle delivery		SmartPharm Therapeutics/Sorrento Therapeutics	Pre-clinical					SmartPharm Therapeutics
82*	Self-assembling vaccine (fusion protein of a heat shock protein and Avidin, with biotinylated immunogenic peptides)		HaloVax (Voltron Therapeutics)/The Vaccine & Immunotherapy Center at the Massachusetts General Hospital	Pre-clinical			Animal study results by October 2020		Voltron Therapeutics press release
83*	LV-SMENP-DC Dendritic cells modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins; administered with antigen-specific cytotoxic T lymphocytes		Shenzhen Geno-Immune Medical Institute	Clinical		NCT04276896 (Shenzhen Geno-Immune Medical Institute)			Nature

* Indicates updated or new field

Number	Type of Vaccine	Related Use/Platform	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
84*	Artificial antigen-presenting cells modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins		Shenzhen Geno-Immune Medical Institute	Clinical		NCT04299724 (Shenzhen Geno-Immune Medical Institute)			Nature
85*	ISR-50		ISR Immune System Regulation	Pre-clinical			Animal study results expected in Q2 2020, Phase 1 begins Q4 2020		ISR Immune System Regulation
86*	Unknown		ImmunoPrecise	Pre-clinical					World Health Organization
87*	Unknown		Tulane University	Pre-clinical					World Health Organization Clinical Trials Arena
88*	Unknown		SK Biosciences	Pre-clinical			Phase 1 begins as early as September 2020		UPI
89*	Unknown		Vir Biotechnology/GSK	Pre-clinical					Vir Biotechnology
90*	Unknown		Precision Vaccines Program at Boston Children's Hospital	Pre-clinical					Scientific American
91*	Unknown, tobacco plant technology		Kentucky BioProcessing (British American Tobacco)	Pre-clinical					BAT
92*	Unknown*		Universite Laval*	Pre-clinical*					World Health Organization*